Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
EMA safety_alert · 2025-09-03Warning about sharp rise in illegal medicines sold in the EU
EMA warns that illegal medicines marketed as GLP-1 receptor agonists for weight loss and diabetes are circulating in the EU, posing serious …
-
EMA safety_alert · 2025-06-06Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 June 2025
EMA's PRAC concluded the safety review of semaglutide medicines and started a safety review of two chickenpox vaccines.
-
EMA safety_alert · 2025-01-17Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January 2025
The EMA's Pharmacovigilance Risk Assessment Committee discussed an investigation into a rare eye condition potentially associated with semag…
-
CLINICAL_TRIALS safety_alert · 2024-09-19Clinical Trial Update: Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes
A completed clinical trial update notes safety signals associated with SGLT2 inhibitors in adults with type 2 diabetes, including risks of u…
-
EMA safety_alert · 2023-10-18EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens
EMA warns about reports of falsified Ozempic pens and provides guidance to patients and healthcare professionals to verify authenticity and …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS safety_alert · 2017-08-30Clinical Trial Update: Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States
A retrospective cohort study using a large US claims database examines the risk of below-knee lower extremity amputation associated with SGL…
-
CLINICAL_TRIALS safety_alert · 2016-09-20Clinical Trial Update: Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments
An AstraZeneca-sponsored clinical trial update documents a risk of hospitalization for severe hypersensitivity reactions, including severe s…
-
CLINICAL_TRIALS safety_alert · 2016-09-20Clinical Trial Update: Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments
A clinical trial update discusses the risk of acute liver failure in patients with type 2 diabetes exposed to oral antidiabetic medications,…
-
CLINICAL_TRIALS safety_alert · 2016-04-19Clinical Trial Update: Incretin-based Drugs and the Risk of Heart Failure
A CNODES observational study update examines whether incretin-based therapies for type 2 diabetes influence the risk of heart failure.
-
CLINICAL_TRIALS safety_alert · 2016-03-14Clinical Trial Update: Incretin-based Drugs and Pancreatic Cancer
A completed observational study assessing whether incretin-based therapies for type 2 diabetes are linked to pancreatic cancer, highlighting…
-
CLINICAL_TRIALS safety_alert · 2016-03-14Clinical Trial Update: High Potency Statins and the Risk of Diabetes
A clinical trial update discusses the potential association between high-potency statins and an increased risk of developing Type 2 diabetes…
-
CLINICAL_TRIALS safety_alert · 2014-07-02Clinical Trial Update: Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine
Clinical trial update noting a potential association between exposure to pravastatin and paroxetine and the development of Type 2 diabetes m…
-
EMA safety_alert · 2013-03-26European Medicines Agency investigates findings on pancreatic risks with GLP-1-based therapies for type-2 diabetes
EMA is investigating pancreatic risk findings associated with GLP-1–based therapies used for type 2 diabetes.
-
EMA safety_alert · 2011-07-21European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer
EMA recommends new contraindications and warnings for pioglitazone to address a small increased risk of bladder cancer.
-
CLINICAL_TRIALS safety_alert · 2011-04-18Clinical Trial Update: Fracture Risk With Thiazolidinediones
A clinical trial update examines fracture risk associated with thiazolidinedione therapy in type 2 diabetes, noting potential increased frac…
-
EMA safety_alert · 2010-09-23European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim
The EMA recommends suspension of the diabetes medicines rosiglitazone-containing products Avandia, Avandamet, and Avaglim due to cardiovascu…
-
EMA safety_alert · 2010-07-22European Medicines Agency update on ongoing benefit-risk review of Avandia, Avandamet and Avaglim
EMA provides an update on the ongoing benefit-risk review of the diabetes medicines Avandia, Avandamet, and Avaglim.
-
EMA safety_alert · 2009-07-29European Medicines Agency update on safety of insulin glargine - Update
EMA update addressing safety considerations for insulin glargine, summarizing ongoing risk assessments and communications to ensure proper u…
-
EMA safety_alert · 2008-01-24EMEA recommends new warnings and contraindications for rosiglitazone
The European Medicines Agency recommends new warnings and contraindications for rosiglitazone to address cardiovascular and other risks.
-
EMA safety_alert · 2007-05-23European Medicines Agency statement on recent publication on cardiac safety of rosiglitazone (Avandia, Avandamet, Avaglim)
EMA issued a statement in response to a publication examining the cardiac safety of rosiglitazone-containing medicines (Avandia, Avandamet, …
-
CLINICAL_TRIALS safety_alert · 2007-02-21Clinical Trial Update: ACEIs and ARBs Treatment in Diabetic Patients -Drug Interactions and Adverse Drug Effects
This clinical trial update discusses potential drug interactions and adverse effects of ACE inhibitors and ARBs in patients with type 2 diab…